Detomidine

Detomidine

Identifiers
IUPAC name 4-[(2,3-dimethylphenyl)methyl]-3H-imidazole
PubChem CID	56032
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H14N2
Molar mass	186.253 g/mol

WikiDoc Resources for Detomidine
Articles
Most recent articles on Detomidine Most cited articles on Detomidine Review articles on Detomidine Articles on Detomidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Detomidine Images of Detomidine Photos of Detomidine Podcasts & MP3s on Detomidine Videos on Detomidine
Evidence Based Medicine
Cochrane Collaboration on Detomidine Bandolier on Detomidine TRIP on Detomidine
Clinical Trials
Ongoing Trials on Detomidine at Clinical Trials.gov Trial results on Detomidine Clinical Trials on Detomidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Detomidine NICE Guidance on Detomidine NHS PRODIGY Guidance FDA on Detomidine CDC on Detomidine
Books
Books on Detomidine
News
Detomidine in the news Be alerted to news on Detomidine News trends on Detomidine
Commentary
Blogs on Detomidine
Definitions
Definitions of Detomidine
Patient Resources / Community
Patient resources on Detomidine Discussion groups on Detomidine Patient Handouts on Detomidine Directions to Hospitals Treating Detomidine Risk calculators and risk factors for Detomidine
Healthcare Provider Resources
Symptoms of Detomidine Causes & Risk Factors for Detomidine Diagnostic studies for Detomidine Treatment of Detomidine
Continuing Medical Education (CME)
CME Programs on Detomidine
International
Detomidine en Espanol Detomidine en Francais
Business
Detomidine in the Marketplace Patents on Detomidine
Experimental / Informatics
List of terms related to Detomidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Detomidine is an imidazole derivative and alpha2-adrenergic agonist, used as a large animal sedative,primarily used in horses. Usually available as detomidine hydrochloride. This is a prescription medication available to veterinarians sold inder the trade name Domosedan.

Properties

Detomidine is a sedative with analgesic properties. Alpha2-adrenergic agonists produce dose-dependent sedative and analgesic effects, mediatated by activation of alpha-2 catecholamine receptors, thus inducing a negative feedback response, reducing production of excitatory neurotransmitters. Due to inhibition of the sympathetic nervous system, detomidine also has cardiac and respiratory effects and an antidiuretic action.

Effects

A profound lethargy and characteristic lowering of the head with reduced sensitivity to environmental stimuli (sounds, etc.) are seen with detomidine. A short period of in-coordination is characteristically followed by immobility and a firm stance with front legs spread. Following administration there is an initial increase in blood pressure, followed by bradycardia and second degree atrioventricular block (this is not pathologic in horses). The horse commonly sweats to excess, especially on the flanks and neck. Other side effects reported include pilo erection (hair standing erect), ataxia, salivation, slight muscle tremors, and (rarely) penile prolapse.

Uses

Sedation and anaesthetic premedication in horses and other large animals, commonly combined with butorphanol for increased analgesia and depth of sedation. In conjunction with ketamine it may also be used for intravenous anaesthesia of short duration. Detomidine is only licenced for use in horses at the present time. The drug is normally administered by the intravenous route, and is fastest and most efficient when given i/v (usually 2-5 minutes to take effect, although this is highly dependent upon the individual and the environment. Some horses are highly resistant to sedation!). However, in recalcitrant animals, detomidine may be administered by the intramuscular or sublingual routes. The dose range advised by the manufacturers is 20-40 mcg/kg i/v for moderate sedation. This dose may need to be higher if given i/m.

Cautions

As detomidine is an arrhythmogenic agent, extreme care should be exercised in horses with cardiac disease, and in the concurrent administration of other arrhythmogenics. The concurrent use of potentiated sulphonamide antibiotics is considered particularly dangerous.

References

• The Ontario Association of Equine Practitioners, Medication Protocols for Horses 2005 <http://www.oaep.on.ca/MedsSheets/MainPage.htm>
• NOAH Compendium of Data Sheets for Animal Medicines 2005